Actively Recruiting
Clonal Hematopoiesis is a Risk Factor for Chemotherapy-Related Complications
Led by Sunnybrook Health Sciences Centre · Updated on 2025-07-08
188
Participants Needed
1
Research Sites
368 weeks
Total Duration
On this page
Sponsors
S
Sunnybrook Health Sciences Centre
Lead Sponsor
T
The Leukemia and Lymphoma Society
Collaborating Sponsor
AI-Summary
What this Trial Is About
'CHIP' stands for Clonal Hematopoiesis of Indeterminate Significance, which are mutations in bone marrow stem cells that give that population of cells a survival or 'clonal' advantage for growth. This study investigates whether CHIP in lymphoma patients aged 60 years and older is a risk factor for chemotherapy-related complications like low blood counts, infections, cardiac events, hospitalizations, dose delays and dose reductions, and failure to recover normal blood counts after chemotherapy finishes.
CONDITIONS
Official Title
Clonal Hematopoiesis is a Risk Factor for Chemotherapy-Related Complications
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of lymphoma such as diffuse large B cell lymphoma, follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, Hodgkin's lymphoma, peripheral T cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic lymphoma, hairy cell leukemia, Waldenstrom's macroglobulinemia, or mantle cell lymphoma
- Starting first or second-line cytotoxic chemotherapy for lymphoma with or without rituximab
- Chemotherapy regimens may include CHOP, CVP, FC, DHAP, ESHAP, GDP, CEOP, or DA-EPOCH
- Age 60 years or older
You will not qualify if you...
- Pre-existing diagnosis of myeloid neoplasm
- Circulating lymphocyte count greater than 10 x 10^9/L
- Significant uncontrolled kidney or liver problems (bilirubin, ALT, or creatinine above 1.5 times the normal upper limit)
- HIV infection
- Active infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Actively Recruiting
Research Team
P
Prasha Sasitharakumar, MHSc
CONTACT
A
Anne Parmentier
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here